All In Biotech

Drug Trial Radar · NCT06620523

Prevent Cardiac Surgery Associated AKI Trial

Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

242

Planned (sponsor's estimate)

Start

Jul 18, 2024

Primary completion

Jun 17, 2027

Study completion Jun 17, 2028

Sponsor

Lead sponsor
George Washington UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Conditions

  • Renal Failure
  • Coronary Artery Disease
  • Surgery
  • Surgery-Complications

Interventions

  • CoQ10 1200 mg orally with Glutathione 1000 mg orallyDrug

    This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury

  • Group B: Placebo CoQ10 orally and Placebo Glutathione orallyDrug

    A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AKI incidence reductionTime frame: 28 days
  2. AKI incidence reductionTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • George Washington University Hospital

    Washington D.C., District of Columbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.